Volunteer for Clinical Studies
Healthy volunteers help NIAID to evaluate treatment and prevention options for a wide range of diseases and conditions in our mission areas. Help us to improve human health.
Alpha-Gal Research at NIAID
Tick bites, particularly those from lone star ticks, can lead to the development of alpha-gal syndrome (AGS), an acquired meat allergy that has no treatment or cure. NIAID supports research to improve understanding of the syndrome with the goal of developing effective therapies or cures.
Ending the HIV Epidemic through Implementation Science
Significant progress has been made over the past four decades to advance the science of HIV diagnostics, prevention, treatment, and care; however, challenges in access, delivery, and uptake can keep these advancements from reaching the communities that need them most. NIAID is continuing to invest in HIV implementation research: the study of approaches for putting public health tools (e.g., treatments, prevention strategies, programs, or procedures) into routine practice.
NIAID’s Support of the Bundibugyo Virus Disease Outbreak Response
When Ebola outbreaks occur, rapid coordination, trusted partnerships, and strong science are essential to support the public health response. NIAID is working with U.S. and international partners to support the Bundibugyo virus disease (BVD) response in the Democratic Republic of the Congo (DRC) and Uganda, identify urgent research needs, and share knowledge and resources from longstanding research.
John H. Powers III, M.D.
John H. Powers III, M.D.
Dr. Powers was named the Acting Director of NIAID in June 2026. He oversees a $6.6 billion budget that supports research to advance the understanding, diagnosis, treatment and prevention of infectious, immunologic, and allergic diseases.
Learn more about Dr. Powers
